Tesis Labs provide white glove customer care by offering customizable genetic testing ranging from carrier screening testing, molecular testing, cancer genomic testing, pharmacogenomics testing, and a wide range of customizable, comprehensive molecular panels using state-of-the-art technologies and equipment.
GRI Labs is licensed by the Nevada State of Health and Human Services, the California State of Health and Human Services, and accredited by the Center for Medicare and Medicaid Services (CMS) as a Clinical Laboratory Improvement Amendments (CLIA) lab. We are also licensed or accredited with a variety of other federal, state, and local authorities. GRI Labs is committed to providing uncompromising and exacting analytical methods. In 2019, GRI Labs achieved an overall score of 99% by COLA Inc., the premier clinical laboratory accreditation, education, and consultation organization in the United States. GRI is a proud member of the California Covid-19 Testing Task Force
We have a team of clinicians, scientists, pathologists, engineers, and technicians unified in our approach of bringing innovation in precision medicine to deliver better data-backed diagnoses and treatments to all communities we serve.
Tesis Labs’ corporate culture is built by medical professionals emphasizing our patient-centric passion to our physician partners. We share the same goal as our clients: quality testing, responsive reporting, and accurate results to ensure your patient’s healthcare needs are met. We are dedicated and focused on providing precision medicine to improve the health and lives of everyone.
Genetic Carrier Disease testing is a diagnostic test that can be done as a normal part of obstetric care. This test, which can be done before you conceive or during pregnancy, can tell you if you and your partner are at risk of passing along certain genetic diseases to your children that you may not have yourself.
Genetic testing involves examining your DNA, the chemical database that carries instructions for your body's functions.
Predictive Genetic Testing can reduce the stress of the unknown, offering clear and actionable results of your genetic risk to key cancers and diseases.
Genetic testing can reveal changes (mutations) in your genes that may cause illness or disease. Catching these mutations early can be key to getting the right treatments (if required).
The obvious benefit of genetic testing is the chance to better understand of your risk for a certain disease. Testing is not perfect, but it can often help you make decisions about your health.
Hereditary cancers are believed to be responsible for 10% of all cancers. Hereditary cancer screenings indicate genetic risk to key cancers and diseases.
Ideal patients have at least one of the following:
- 3 or more first-degree relatives (mother, father, sisters, brothers, children) with any of the top 6 cancers that are affiliated with BRCA 1 & 2 (breast, ovarian, uterine, prostate, pancreatic, and colorectal)
- 3 or more relatives on one side of his/her family who have had the same type of cancer
- A cluster of cancers in his/her family that are known to be linked to a single gene mutation (such as breast, ovarian and pancreatic cancers)
- A known genetic mutation in one or more family members who have already had genetic testing
- A personal history of cancer
- Hereditary Cancer Test Result Possibilities
Negative: The patient does not have genetic variations that indicate that he/she is at increased risk of developing cancer.
VUS (Variant of Unspecified Significance): The patient does have genetic variations, but these variations do not indicate that he/she is at increased risk of developing cancer.
Positive: The patient does have genetic variations which indicate that he/she is at increased risk of developing cancer.
*Results are not a guarantee that a patient will or will not receive a diagnosis of cancer.
We believe that the future of cancer isn’t in how we treat it, but in how quickly we are aware of the presence and make-up of the cancer. Hereditary cancer is believed to be responsible for 10% of all diagnosed cancers; our non-invasive hereditary cancer screening can let you know if you are genetically predisposed to certain hereditary cancers. The process is a simple buccal swab provided by us, followed by next generation sequencing, an advanced technology that lets us to look at multiple strands of your DNA at the same time. While this test cannot definitively tell you if you will or will not get cancer, it does allow you and your health care provider to create a proactive plan for your future.
Patients with the following personal or family history may qualify for Cardiomyopathy:
Benefits of Detection: This panel is for patients who have a personal or family history of Parkinson’s disease, Alzheimer’s disease or dementia. While genetics are not believed to be the sole cause of these diseases, research does show that abnormal changes in genes are a contributing factor with their onset. These genetic changes and abnormalities may be passed down in families. Children, siblings and parents of patients who are determined to have this genetic variation are 50% more likely to also be at increased risk. Detection of gene variations or abnormalities associated with Parkinson’s disease, Alzheimer’s disease and/or dementia does not mean that an individual will develop one of these diseases. Awareness of the potential does allow families the opportunity to plan ahead, make precautionary and predetermined care decisions, participate in research studies, and identify support networks for caregivers and patients.
Warning Signs and Treatments: Abnormal imaging of the brain, memory loss that interferes with daily life and functioning, mood and personality changes, difficulty carrying on conversations, inability to complete familiar tasks, confusion with time and places and problems moving or controlling movement. Although there is currently no cure for Parkinson’s disease, Alzheimer’s disease or dementia, there are treatments and procedures available that have shown success slowing the progression of these diseases and lessening the severity of the patient’s symptoms.
Approximately 1 million Americans are currently living with Parkinson’s disease and 5 million are suffering from Alzheimer’s disease.
Alzheimer’s disease, Parkinson’s disease, and dementia are conditions that affect the brain and spinal cord. Research has shown that these diseases can sometimes be caused by abnormal changes in our genes, and these genetic changes can be inherited and passed down in families. Having a family history of Parkinson’s disease, Alzheimer’s disease, dementia, or a similar condition may increase your risk of having that condition. Genetic testing can help a patient with the planning and decision-making process for treatment of their disease. This panel is for patients who have a personal or family history of Parkinson’s disease, Alzheimer’s disease, or dementia. Some warning signs of these diseases include abnormal imaging of the brain, difficulty moving or controlling one’s movement, memory loss that interferes with daily life, changes in mood or personality, difficulty having a conversation or completing familiar tasks, and confusion with the time or place.
Respiratory Pathogen Panel
Upper respiratory infections are one of the most common reasons for physician visits. These infections can be viral, bacterial, mycoplasia or fungal in their origin. Research shows that while 90-98% of upper respiratory infections are actually viral, 65% of patients seen for a URI are prescribed an antibiotic. NS Genomics offers a quick turnaround time so that patients can receive the treatment they need sooner and, should antibiotics be needed, recommends the most effective antibiotic for the infection detected.
Gastrointestinal infections can be viral, bacterial or parasitic. Most are self-resolving and do not require pharmaceutical intervention. Treating these infections with antibiotics when not necessary or with the wrong antibiotics can exacerbate the situation and create additional medical issues. NS Genomics offers a 31 pathogen panel to identify the correct source of illness and, if needed, the appropriate antibiotics for successful treatment.
50% of nail disorders are bacterial and 50% are fungal. NS Genomics’ panel tests nail and infected adjacent tissue for 29 fungal pathogens and 29 bacterial pathogens. The resulting report guides physicians towards appropriate treatments.
The FH Panel looks at 5 genes associated with familial hypercholesterolemia.
•Patients with a personal and/or family history suggestive of a FH should consider this screening and are considered at risk if there are high cholesterol levels, very high levels of low-density lipoprotein, and cardiovascular disease.
•Patients identified with FH can benefit from increased surveillance and preventative steps to better manage their risks. Medical intervention may include a combination of medication therapy, low-fat diet, exercise, weight control and not smoking. A patient with a positive result may encourage family members to be tested to help define their risk. If a pathogenic variant is identified in your patient, close relatives (children, siblings, parents) could have as high as a 50%risk to also be at increased risk. In some cases, screening should begin in childhood.
Adverse drug reactions are the 4th leading cause of death in America and, according to the FDA, the reason 4.5 million Americans visit their doctor’s office or the ER every year. Pharmacogenomics is the study of your unique genetic makeup and how it influences drug effectiveness in order to personalize a patient’s drug therapy. Currently, medications are prescribed based on a patient’s weight, height, gender, condition, and previous drug history resulting in trial and error. There are many pathways in our body that metabolize drugs and seemingly small genetic variations can contribute to an adverse drug reaction. These risks can be significantly minimized through pharmacogenomic testing. NS Genomics’ testing can identify the way that a patient metabolizes a drug and assist providers in choosing ideal and unique drug combinations.
Genetic profiles contain six enzymes that metabolize 90 percent of all medications patients are given. These genes and enzymes help determine each individual’s rate of metabolism. These profiles can reveal if a patient processes medication too quickly or too slowly; both can cause complications. Research shows that people fall into one of four general metabolizer types:
•Poor metabolizer: Patients who are poor metabolizers experience a very slow breakdown of medications, making side effects more pronounced. That means standard doses of certain medications may not work as intended.
•Intermediate metabolizer: A slowed metabolism may impact breakdown of medications, causing effects similar to poor metabolizers, but not as pronounced.
•Extensive metabolizer: Considered a “normal” rate of metabolism. Patients are likely to metabolize medication normally and medication is likely to work as intended.
•Ultra rapid metabolizer: Patients in this group metabolize medications too quickly to experience relief from symptoms of depression or other disorders.
Make an Appointment
COVID-19 is a Respiratory infection that has attributed to over 80% of all COVID19 deaths in the United States over 65.
If you’re a Senior, over 65 and symptomatic, call 1-877-403-4554 Today to get tested for R-P-P-COVID-19 in the comfort of your own home or Senior Living Center. If you qualify…a licensed Medical professional will come to your home to perform the test!
COVID-19 is the silent killer of our Seniors and it’s not going away!